TerminatedNCT00160147

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Medication studyAges 65–90Multiple countriesSchizophrenia

The study in practice

Understand this study

Listed age limits: 65 years to 90 years.

Listed locations: Phoenix and 50 more locationsSee all locations and recruitment
Study phase: Phase 3

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateDecember 2005

Recruitment status: Terminated
Enrollment listed in the registry: 60
Sponsor: Solvay Pharmaceuticals
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States, Czechia, Estonia, ...
Age range: From 65 Years to 90 Years
Official registry ID: NCT00160147
Official title: Show the full official title
A Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Terminated

Phoenix, United States · Carson, United States · Long Beach, United States

45 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Solvay Pharmaceuticals.

Does this study involve medication?

Yes. The study involves medication, including bifeprunox and Placebo.

Who can participate?

Listed age limits: 65 years to 90 years.

Is this study still recruiting?

The registry lists this study as terminated.